The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

The unraveling of the Novo-Hims relationship not only erased billions in market value but also served as a stark reminder of the dangers of using leveraged ETFs. - For most investors, leveraged ETFs ...

A nasty dip for Hims HIMS Monday. Novo Nordisk confirmed that they are terminating their collaboration with the company due to concerns about their “illegal mass compounding and deceptive marketing.” ...

2025年6月24日， Hims & Hers Health（HIMS）披露1笔公司内部人交易情况。高管Okupe Oluyemi于2025年6月23日卖出2.31万股。 Hims & Hers Health, ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...